BACKGROUND: Iron supplementation could improve the hematopoietic response of erythropoiesis-stimulating agents (ESAs) used for chemotherapy-induced anemia. METHODS: We performed a meta-analysis of randomized, controlled trials by comparing parenteral or oral iron and no iron, when added to ESAs in anemic cancer patients, in order to calculate the relative risk (RR) of hematopoietic response and transfusions, the time required to reach this response, and toxicity. RESULTS: A total of 1,606 patients out of eight trials were available for meta-analysis. The RR of obtaining an hematopoietic response was 1.29 (P = 0.0001) with parenteral iron and 1.04 for oral iron (P = 0.59). The risk of transfusion was reduced with parenteral iron versus no iron (RR 0.77; P = 0.02) but not with oral iron (RR 0.68; P = 0.08). The time to reach hematopoietic response was 1 month shorter and no increased toxicity appeared with iron supplementation. CONCLUSION: Overall parenteral iron reduces the risk of transfusions by 23% and increases the chance of hematopoietic response by 29% when compared with ESAs alone. On the contrary, oral iron does not increase hematopoietic response nor transfusion rate. The significance of these results is that the proportion of non-responders to ESAs will have strongly improved and quality of life and cost ameliorated.
BACKGROUND:Iron supplementation could improve the hematopoietic response of erythropoiesis-stimulating agents (ESAs) used for chemotherapy-induced anemia. METHODS: We performed a meta-analysis of randomized, controlled trials by comparing parenteral or oral iron and no iron, when added to ESAs in anemic cancerpatients, in order to calculate the relative risk (RR) of hematopoietic response and transfusions, the time required to reach this response, and toxicity. RESULTS: A total of 1,606 patients out of eight trials were available for meta-analysis. The RR of obtaining an hematopoietic response was 1.29 (P = 0.0001) with parenteral iron and 1.04 for oral iron (P = 0.59). The risk of transfusion was reduced with parenteral iron versus no iron (RR 0.77; P = 0.02) but not with oral iron (RR 0.68; P = 0.08). The time to reach hematopoietic response was 1 month shorter and no increased toxicity appeared with iron supplementation. CONCLUSION: Overall parenteral iron reduces the risk of transfusions by 23% and increases the chance of hematopoietic response by 29% when compared with ESAs alone. On the contrary, oral iron does not increase hematopoietic response nor transfusion rate. The significance of these results is that the proportion of non-responders to ESAs will have strongly improved and quality of life and cost ameliorated.
Authors: J Douglas Rizzo; Melissa Brouwers; Patricia Hurley; Jerome Seidenfeld; Murat O Arcasoy; Jerry L Spivak; Charles L Bennett; Julia Bohlius; Darren Evanchuk; Matthew J Goode; Ann A Jakubowski; David H Regan; Mark R Somerfield Journal: J Clin Oncol Date: 2010-10-25 Impact factor: 44.544
Authors: Michael Auerbach; Peter T Silberstein; R Timothy Webb; Svetlana Averyanova; Tudor-Eliade Ciuleanu; James Shao; Kenneth Bridges Journal: Am J Hematol Date: 2010-09 Impact factor: 10.047
Authors: Michael Hedenus; Magnus Adriansson; Jesus San Miguel; Mark H H Kramer; Martin R Schipperus; Eeva Juvonen; Kerry Taylor; Andrew Belch; Albert Altés; Giovanni Martinelli; David Watson; James Matcham; Gregory Rossi; Timothy J Littlewood Journal: Br J Haematol Date: 2003-08 Impact factor: 6.998
Authors: Laurent Bastit; An Vandebroek; Sevilay Altintas; Bernd Gaede; Tamás Pintér; Tamas S Suto; Tony W Mossman; Kay E Smith; Johan F Vansteenkiste Journal: J Clin Oncol Date: 2008-04-01 Impact factor: 44.544
Authors: Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506
Authors: D Kotasek; G Steger; W Faught; C Underhill; E Poulsen; A B Colowick; G Rossi; J Mackey Journal: Eur J Cancer Date: 2003-09 Impact factor: 9.162
Authors: Heinz Ludwig; Rayko Evstatiev; Gabriela Kornek; Matti Aapro; Thomas Bauernhofer; Veronika Buxhofer-Ausch; Michael Fridrik; Dietmar Geissler; Klaus Geissler; Heinz Gisslinger; Elisabeth Koller; Gerhard Kopetzky; Alois Lang; Holger Rumpold; Michael Steurer; Houman Kamali; Hartmut Link Journal: Wien Klin Wochenschr Date: 2015-09-15 Impact factor: 1.704
Authors: Jean-Loup Mouysset; Beata Freier; Joan van den Bosch; Charles Briac Levaché; Alain Bols; Hans Werner Tessen; Laura Belton; G Chet Bohac; Jan-Henrik Terwey; Giuseppe Tonini Journal: Cancer Manag Res Date: 2016-01-21 Impact factor: 3.989
Authors: Antonino Mafodda; D Giuffrida; A Prestifilippo; D Azzarello; R Giannicola; M Mare; R Maisano Journal: Support Care Cancer Date: 2017-04-09 Impact factor: 3.603